BCL2 and cancer: Thus, at least for BH3 mimetics, structure-based design and fine modulation of their selectivity and activity undoubtedly represent a perspective approach for enlarging the family of potent and safe anti-cancer drugs targeting anti-apoptotic BCL2 family proteins [69,70].